VAXIMM AG
VAXIMM Announces Presentations at Upcoming Industry and Scientific Events
DGAP-News: VAXIMM AG / Key word(s): Conference VAXIMM Announces Presentations at Upcoming Industry and Scientific Events – Company to present at several partnering and investor forums – Preclinical data with oral T-cell immunotherapy platform to be presented at EORTC-NCI-AACR Symposium Basel (Switzerland) and Mannheim (Germany), October 26, 2016 – VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that management will be presenting at several upcoming events in October and November. Equity Forum 2016: Cancer Immunotherapy – a STANDARD emerging! BIO-Europe(R) – 2016 – 22nd Annual International Partnering Conference German Equity Forum (Deutsches Eigenkapitalforum) In addition, preclinical data from VAXIMM’s oral T-cell immunotherapy platform will be presented at an important scientific conference later this fall: EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium About VAXIMM: VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor. VAXIMM’s lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including pancreatic, colorectal and brain cancer. In addition to VXM01, VAXIMM has a pipeline of complementary development candidates targeting different tumor structures. VAXIMM’s investors include BB Biotech Ventures, Merck Ventures, Sunstone Capital and BioMed Partners. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s clinical operations. For more information, please see www.vaximm.com. Contact: Media Inquiries:
2016-10-26 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |